sirolimus

(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

QFJCIRLUMZQUOT-HPLJOQBZSA-N CHEBI:9168 8 Reactome links 2 studies

2 Observed studies

3 Observed diff profiles

8 Reactome pathways

Metabolite details

Identifier: QFJCIRLUMZQUOT-HPLJOQBZSA-N
InChI Key: QFJCIRLUMZQUOT-HPLJOQBZSA-N
IUPAC name: (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
Preferred name: sirolimus
INN name: sirolimus
Synonym: (-)-Rapamycin
ChEBI: CHEBI:9168

Reactome pathways

R-HSA-162582 - Signal Transduction
R-HSA-1643685 - Disease
R-HSA-165159 - MTOR signalling
R-HSA-166208 - mTORC1-mediated signalling
R-HSA-5663205 - Infectious disease
R-HSA-9679191 - Potential therapeutics for SARS
R-HSA-9679506 - SARS-CoV Infections
R-HSA-9824446 - Viral Infection Pathways

Observed in studies

Observed in differential profiles